US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:

• Ngā kaituhi matua: Athena L. Huang, MD (Author), Ann Marie Navar, MD, PhD (Author), Colby Ayers, MS (Author), Anand Rohatgi, MD, MSCS (Author), Erin Michos, MD, MHS (Author), Salim Virani, MD, PhD (Author), Parag Joshi, MD, MHS (Author), Eric Peterson, MD, MPH (Author), Amit Khera, MD, MSc (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2023-09-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Therapeutic Area: CVD Prevention - Primary and Secondary Background: Aspirin for the primary prevention of cardiovascular disease (CVD) remains controversial. The 2022 US Preventive Services Task Force (USPSTF) guidelines give a grade C recommendation to consider aspirin use for primary prevention i...